Harnessing the Power of ROR1

VelosBio is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer.

About Us

ROR1-Targeted
Therapies

ROR1 cell-surface protein is expressed on many hematologic and solid tumors. VelosBio’s proprietary ROR1-targeting technology allows the selective delivery of ROR1-directed therapies to tumors while sparing normal tissues.

Our Science
Homepage Bi Ab alt

Patient-Focused,
Science-Driven

Led by industry veterans with a track record of delivering new oncology drugs to patients, VelosBio Inc. is committed to improving patient outcomes by creating innovative targeted therapies for patients with hematologic and solid tumor malignancies.

Now Leaving The VelosBio Site.

VelosBio Inc. is now a wholly-owned subsidiary of Merck & Co., Inc. (Kenilworth, New Jersey USA)

CLICK TO VISIT www.merck.com